SCHEMBL29697132

SCHEMBL29697132

NCC(=O)N[C@H](CC(N)=O)C(=O)NCC(=O)O

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.44
GSTK1 Q9Y2Q3 1/20 0.44
GLO1 Q04760 1/20 0.39
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38
PTGS2 P35354 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
ECE1 P42892 5/20 0.37
GRIA1 P42261 1/20 0.35
GRIA3 P42263 1/20 0.35
MMP8 P22894 1/20 0.34
MME P08473 2/20 0.33
ACE P12821 1/20 0.33
CPA1 P15085 1/20 0.33
ACE2 Q9BYF1 1/20 0.33
CTSC P53634 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL148088 1.00 PTGS1 (0.44) PTGS1GSTK1GLO1ALDH1A1LMNA
SCHEMBL16094750 0.97 PTGS1 (0.43) PTGS1GSTK1GLO1ALDH1A1LMNA
SCHEMBL901070 0.97 PTGS1 (0.43) PTGS1GSTK1GLO1ALDH1A1LMNA
SCHEMBL6928953 0.97 PTGS1 (0.43) PTGS1GSTK1GLO1ALDH1A1LMNA
SCHEMBL6129326 0.97 PTGS1 (0.43) PTGS1GSTK1GLO1ALDH1A1LMNA
SCHEMBL7571502 0.95 PTGS1 (0.42) PTGS1GSTK1GLO1ALDH1A1LMNA
SCHEMBL3493292 0.95 PTGS1 (0.42) PTGS1GSTK1GLO1ALDH1A1LMNA
SCHEMBL8448660 0.95 PTGS1 (0.42) PTGS1GSTK1GLO1ALDH1A1LMNA
SCHEMBL6136563 0.95 PTGS1 (0.42) PTGS1GSTK1GLO1ALDH1A1LMNA
SCHEMBL1472099 0.95 PTGS1 (0.42) PTGS1GSTK1GLO1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250011367-A1 CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF ENTRADA THERAPEUTICS, INC. 2025-01-09 US disclosed
US-20220177523-A1 CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF ENTRADA THERAPEUTICS, INC. 2022-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250011367-A1 CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF VIP, LNPEP, TAP1 PTGS1 4293/4885GSTK1 3410/4885GLO1 4536/4885
US-20220177523-A1 CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF VIP, LNPEP, TAP1 PTGS1 4293/4885GSTK1 3410/4885GLO1 4536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.